Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Material agreement · Other material event · Item 3.02 · +1 more
BriaCell Therapeutics Corp.
17
Material agreement
Jun 3, 2026
| Item 1.01 | Entered a material definitive agreement |
| Item 3.02 | Item 3.02 |
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
BriaCell Therapeutics Corp. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
1 BriaCell Therapeutics Announces Pricing of Offering Philadelphia & Vancouver, British Columbia – May 31, 2026 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares.
This filing reports Item 1.01 (entered a material definitive agreement); Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
BriaCell Therapeutics Corp. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
